Cancer Cause and Prevention Research federal funding in FY2024

Cancer Cause and Prevention Research × FY2024 is CFDA 93.393, not a screening-rate table, an incidence atlas, or a Cancer Biology Research twin

$5,102,786,615.09 is the obligation sum USAspending.gov attributes to Cancer Cause And Prevention Research in FY2024 on the yearlyTrend series. It is not the government-wide FY2024 total and not an outlay. The FY cell is 86.3% of the program-wide $5,915,477,684.62 book in this extract. Campaign-finance filings do not fund these USAspending obligations. Do not invent contractors or award recipients; this packet lists none.

Readers sometimes treat a CFDA–year total as a budget Congress passed for a named activity. $5,102,786,615.09 is not that. It is the USAspending obligation rollup tagged to Cancer Cause And Prevention Research and fiscal year 2024. Cite both sides. Unique recipients are unpublished.

Unpacking the Cancer Cause And Prevention Research side

The catalog string is CANCER CAUSE AND PREVENTION RESEARCH. CFDA 93.393 is the program parent without a FY2024 filter. Program-wide obligations $5,915,477,684.62 and 2,497 parent awards describe that parent, not the year cell alone. Confusing this join with Cancer Biology Research (CFDA 93.396) and other cancer catalog lines would leave this overlay. Cancer Cause And Prevention Research is CFDA 93.393. It is not Cancer Biology Research on 93.396. FY2024 cells for those two listings are separate overlays. Combining them would invent a merged cancer-research total this packet does not publish. Trial names, sites, and exposure datasets are unpublished.

SpendingVault does not grade Cancer Cause and Prevention Research on outcomes. $5,102,786,615.09 is an obligation sum, not a scorecard. Place-of-performance geography is unpublished here.

Unpacking fiscal year 2024

FY2024 federal spending is the year parent without a CFDA 93.393 filter. FY2024 figures can be incomplete for a current year. Awards that list another fiscal year sit outside this cell. Do not treat $5,915,477,684.62 as the FY2024 headline. Calendar-year statistics are not this time key.

1,975 award records versus 1,975 unique studies or 1,975 screened patients

1,975 year-cell awards are not 1,975 unique studies or 1,975 screened patients. Dividing $5,102,786,615.09 by 1,975 yields about $2,583,689.43, a quotient, not a typical invoice. Modifications can add rows. The parent count 2,497 is an all-year table. Mixing the year dollars with the parent count invents a per-award figure this packet does not publish.

Caveats on Cancer Cause and Prevention Research obligations in FY2024

An obligation is a commitment. An outlay is a Treasury payment. $5,102,786,615.09 is the commitment figure. The join cannot support a named-trial roster, a risk-factor scoreboard, or a prevention-campaign census. Keep the obligation label. If a chart mixes Cancer Biology Research (CFDA 93.396) and other cancer catalog lines with CFDA 93.393 in FY2024, the chart has left this join.

Hubs: /programs/93.393/ (CFDA 93.393), /fiscal-years/2024/ (FY2024 federal spending), /programs/ (All programs), /ties/ (All spending ties). None convert this cell into a recipient list. Cite Cancer Cause And Prevention Research, FY2024, CFDA 93.393, $5,102,786,615.09, 1,975 awards, USAspending.gov, obligations only. Keep Cancer Cause And Prevention Research and FY2024 on the same line as $5,102,786,615.09. CFDA 93.393 remains the program key; fiscal year 2024 remains the time key. Obligations of $5,102,786,615.09 are not outlays and not a named-trial roster, a risk-factor scoreboard, or a prevention-campaign census. Original filings remain on USAspending.gov for this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. Unique recipients remain unpublished on this program-year join. All programs and All spending ties are larger indexes than this cell. A later USAspending ingest can restate $5,102,786,615.09 without changing CFDA 93.393 or FY2024. Do not invent contractors or award recipients for Cancer Cause and Prevention Research. The 1,975 year-cell awards are still not 1,975 unique studies or 1,975 screened patients.

Questions

How much Cancer Cause and Prevention Research spending is in FY2024?

USAspending.gov records $5,102,786,615.09 in Cancer Cause And Prevention Research obligations for FY2024 (CFDA 93.393). That is a program × year join, not an outlay and not the government-wide FY2024 total. Original filings remain on USAspending.gov.

Do 1,975 awards mean 1,975 prevention trials in FY2024?

No. 1,975 is the year-cell award-record count, not 1,975 unique studies or 1,975 screened patients. A mean of about $2,583,689.43 is arithmetic on packet facts, not a typical payment. Unique recipients are unpublished. Original filings remain on USAspending.gov.

Is $5,102,786,615.09 cash already paid for Cancer Cause and Prevention Research in FY2024?

No. $5,102,786,615.09 is an obligation aggregate for Cancer Cause And Prevention Research in FY2024. Outlays, remaining balances, and cash already paid are unpublished on this packet. Keep the obligation label. USAspending.gov remains the source. Keep Cancer Cause And Prevention Research and FY2024 together when citing $5,102,786,615.09.

Which pages parent Cancer Cause and Prevention Research FY2024?

CFDA 93.393 is the program parent. FY2024 federal spending is the year parent. All programs lists other CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Cancer Cause And Prevention Research × FY2024 at $5,102,786,615.09.